With Indian pharma under the scanner, 60 firms register under Centre’s scheme to upgrade their manufacturing facilities

Xin Weisheng

Home > News > INDUSTRY NEWS >

12 Jul 2024
With Indian pharma under the scanner, 60 firms register under Centre’s scheme to upgrade their manufacturing facilities
New Delhi: Sixty small drug makers have joined a government scheme that promises financial incentives for modernizing their units in keeping with Indian attempts to sync with global good manufacturing practices.

The move comes after a string of Indian-made drugs in regions as far afield as North America, Africa and Central Asia were found to be toxic, causing fatalities and raising questions about Indian pharma exports.

Over 30 firms have already started upgrading their manufacturing units under the Revamped Pharmaceuticals Technology Upgradation Assistance Scheme (RPTUAS).

The Centre last year revised the Drugs and Cosmetic Act to make it mandatory for companies to follow World Health Organization-recommended good manufacturing practices (GMP).

“To help smaller plants, the scheme is facilitating existing pharma units to upgrade to revised standards. A portal has been opened wherein 60 plants have registered on it and they are being trained or assisted to follow GMP rules and upgrade themselves and 30 plants have already started their operations in terms of upgrading their facilities,” said an official aware of the matter on the condition of anonymity.

“The government is encouraging more such plants to come and join the scheme and take benefit in terms of upgrading themselves,” the official said. The scheme gives preference to micro, small and medium enterprises (MSMEs), supporting smaller players achieve high standards.

Queries sent to the department of pharmaceuticals spokesperson remained unanswered till press time.

Pharma firms which have had an average revenue of less than Rs.500 crore over the last 3 years are eligible for incentives of a maximum of ₹1 crore per unit.

Firms with an average revenue of ₹1crore to less than ₹50 crore will get paid 20% of investments. Firms with a revenue of ₹50 crore to less than ₹250 crore are eligible to 15% of investment while those with revenue of ₹250 crore to less than ₹500 crore are eligible for 10% of investment.

They must invest in “eligible activities” including heating, ventilation, and air conditioning, water and steam utilities, testing laboratories, stability chambers, clean rooms, effluent treatment, waste management etc.

“Most of the companies that have registered are MSMEs and more are likely to join soon. GMP compliance is of the highest standards and that is why it is taking time for companies to upgrade their facilities. It is easier to start a new factory than to upgrade the existing one. We are educating our member companies on GMP standards as the new guidelines have undergone drastic changes this time,” said Harish K Jain, president, Federation of Organizations of Pharmaceutical Entrepreneurs (FOPE).

(Source: LiveMint)
  • wechat
Recent Posts
  • Biosphere zaps germs with UV light to make biomanufacturing cheaper
    09 Jan 2025
    Biosphere zaps germs with UV light to make biomanufacturing cheaper
    Find out more
  • China's API Dominance Reshapes Global Pharmaceutical Supply Chains
    04 Dec 2024
    China's API Dominance Reshapes Global Pharmaceutical Supply Chains
    Find out more
  • From mundane to marvelous: The current and future uses of AI
    13 Nov 2024
    From mundane to marvelous: The current and future uses of AI
    Find out more

WANT TO KNOW MORE ABOUT HOW OUR

SOLUTIONS CAN HELP YOU?

Cookies
Our site uses cookies. We’d also like to set optional cookies to give you the best experience and porvide you relevant advertising. You can choose to manage your preferences or accept all cookies. You can also read our Privacy Policy and Cookie Policy for more information.